Table 1 Characteristics of studies included in the meta-analysis
Study | Country | Year | PC case | Died from PC or develop lethal PC | Type of study | Drugs studied | Treatment | HR, 95% CI |
|---|---|---|---|---|---|---|---|---|
Veitonm€aki | Finland | 2015 | 6537 | 617 | cohort | aspirin/NSAID | RP, RT, ADT or observe NSAID | 1.067(0.774–1.471) |
Downer | USA | 2017 | 3277 | 492 | cohort | aspirin | RP, RT | 0.645(0.488–0.852) |
Flahavan | Ireland | 2014 | 2936 | 276 | cohort | aspirin | RP, RT, ADT | 0.88(0.67–1.15) |
Jacobs | USA | 2014 | 8427 | 441 | cohort | aspirin | RP, RT, ADT | 0.946(0.788–1.135) |
Zhou | USA | 2017 | 26,890 | 975 | cohort | aspirin/NSAID | RP, RT, ADT | 0.976(0.874–1.09) |
Assayag | Canada | 2015 | 11,779 | 1793 | cohort | aspirin | RP, RT, ADT | 1.46(1.29–1.65) |
Hurwitz | USA | 2018 | 817 | 90 | cohort | aspirin/NSAID | NR | 0.59(0.36–0.96) |
Choe | USA | 2012 | 5955 | 193 | cohort | aspirin | RP, RT | 0.43(0.21–0.87) |
Rothwell | UK | 2011 | Nr | Nr | cohort | aspirin | NR | 0.52(0.2–1.34) |
Stock | Canada | 2008 | 1619 | 453 | cohort | NSAID | RP, RT | 1.03(0.79–1.34) |